Precigen (PGEN) Receivables - Net (2012 - 2026)
Precigen (PGEN) reported Receivables - Net of $26.4 million for Q1 2026, up 3415.71% year-over-year from $751000.0 in Q1 2025, and up 574.23% quarter-over-quarter from $3.9 million in Q4 2025.
Precigen (PGEN) Receivables - Net (2012 - 2026) Analysis & Trends
Precigen (PGEN) has 15 years of Receivables - Net data on file, last reported at $26.4 million in Q1 2026.
- Receivables - Net for Q1 2026 came in at $26.4 million, up 3415.71% year-over-year; the trailing twelve-month figure through Mar 2026 was $26.4 million (up 3415.71% YoY), and the FY2025 annual result was $3.9 million, up 322.89% from the prior year.
- Receivables - Net advanced to $26.4 million in Q1 2026 per PGEN's latest filing, from $3.9 million in the prior quarter.
- Over five years, Receivables - Net peaked at $26.4 million in Q1 2026 and troughed at $327000.0 in Q2 2025.
- A 5-year average of $4.0 million and a median of $978000.0 in 2022 frame the typical range for Receivables - Net.
- The sharpest annual moves came in 2022 and 2026: Receivables - Net sank 94.98% in 2022, then jumped 3415.71% in 2026.
- A 5-year view of Receivables - Net shows it stood at $978000.0 in 2022, then declined by 7.77% to $902000.0 in 2023, then increased by 2.66% to $926000.0 in 2024, then jumped by 322.89% to $3.9 million in 2025, then jumped by 574.23% to $26.4 million in 2026.
- Business Quant data shows PGEN's Receivables - Net at $26.4 million in Q1 2026, $3.9 million in Q4 2025, and $580000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - |
| 10 | Precigen | 1.27 Bn | 1.27 Bn | 20.69 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 26.40 Mn |
| Mar 31, 2026 | 26.40 Mn |
| Dec 31, 2025 | 3.92 Mn |
| Dec 31, 2025 | 3.92 Mn |
| Sep 30, 2025 | 580,000.00 |
| Sep 30, 2025 | 580,000.00 |
| Jun 30, 2025 | 327,000.00 |
| Jun 30, 2025 | 327,000.00 |
| Mar 31, 2025 | 751,000.00 |
| Mar 31, 2025 | 751,000.00 |
| Dec 31, 2024 | 926,000.00 |
| Dec 31, 2024 | 926,000.00 |
| Sep 30, 2024 | 479,000.00 |
| Sep 30, 2024 | 479,000.00 |
| Jun 30, 2024 | 511,000.00 |
| Jun 30, 2024 | 511,000.00 |
| Mar 31, 2024 | 872,000.00 |
| Mar 31, 2024 | 872,000.00 |
| Dec 31, 2023 | 902,000.00 |
| Dec 31, 2023 | 902,000.00 |